Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the … Read more
Oncopeptides AB (publ) (ONPPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -1.317x
Based on the latest financial reports, Oncopeptides AB (publ) (ONPPF) has a cash flow conversion efficiency ratio of -1.317x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.50 Million) by net assets ($54.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncopeptides AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Oncopeptides AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncopeptides AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncopeptides AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ONEJOON Co. Ltd.
KQ:382840
|
0.080x |
|
Asian Energy Services Limited
NSE:ASIANENE
|
0.019x |
|
Gevelot
PA:ALGEV
|
0.028x |
|
Foseco India Limited
NSE:FOSECOIND
|
0.127x |
|
Lam Dong Mineral and Building Material JSC
VN:LBM
|
N/A |
|
Stratec SE
PINK:STSEY
|
0.018x |
|
Horizon Space Acquisition II Corp. Ordinary share
NASDAQ:HSPT
|
-0.004x |
|
Prevas AB Series B
LSE:0H2J
|
0.117x |
Annual Cash Flow Conversion Efficiency for Oncopeptides AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of Oncopeptides AB (publ) from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $54.28 Million | $-260.57 Million | -4.800x | +2.49% |
| 2023-12-31 | $56.78 Million | $-279.49 Million | -4.922x | -244.49% |
| 2022-12-31 | $294.29 Million | $-420.51 Million | -1.429x | +80.13% |
| 2021-12-31 | $210.87 Million | $-1.52 Billion | -7.191x | -219.98% |
| 2020-12-31 | $576.90 Million | $-1.30 Billion | -2.247x | -159.38% |
| 2019-12-31 | $797.01 Million | $-690.57 Million | -0.866x | +18.00% |
| 2018-12-31 | $315.83 Million | $-333.73 Million | -1.057x | -62.69% |
| 2017-12-31 | $418.00 Million | $-271.50 Million | -0.650x | +83.59% |
| 2016-12-31 | $26.34 Million | $-104.26 Million | -3.959x | -119.49% |
| 2015-12-31 | $-2.60 Million | $-52.81 Million | 20.311x | +591.36% |
| 2014-12-31 | $7.61 Million | $-31.44 Million | -4.134x | -- |